statistiche ricercatore

Continente	#
NA - Nord America	615
AS - Asia	376
EU - Europa	289
SA - Sud America	119
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	15
OC - Oceania	1
Totale	1.430

Nazione	#
US - Stati Uniti d'America	574
IT - Italia	186
SG - Singapore	122
CN - Cina	96
BR - Brasile	90
VN - Vietnam	82
HK - Hong Kong	26
DE - Germania	19
CA - Canada	16
SE - Svezia	15
AR - Argentina	14
FR - Francia	12
GB - Regno Unito	12
RU - Federazione Russa	11
IN - India	8
BD - Bangladesh	7
JP - Giappone	7
PL - Polonia	7
IQ - Iraq	6
ES - Italia	5
ID - Indonesia	5
MX - Messico	5
NL - Olanda	5
ZA - Sudafrica	5
AT - Austria	4
MA - Marocco	4
PK - Pakistan	4
TR - Turchia	4
CO - Colombia	3
CR - Costa Rica	3
JM - Giamaica	3
SV - El Salvador	3
UA - Ucraina	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
CH - Svizzera	2
EC - Ecuador	2
FI - Finlandia	2
GP - Guadalupe	2
GT - Guatemala	2
HN - Honduras	2
LT - Lituania	2
PE - Perù	2
PR - Porto Rico	2
PY - Paraguay	2
UZ - Uzbekistan	2
AL - Albania	1
BF - Burkina Faso	1
BO - Bolivia	1
CL - Cile	1
CW - ???statistics.table.value.countryCode.CW???	1
EG - Egitto	1
ET - Etiopia	1
IE - Irlanda	1
IL - Israele	1
KE - Kenya	1
KN - Saint Kitts e Nevis	1
MY - Malesia	1
NI - Nicaragua	1
NP - Nepal	1
NZ - Nuova Zelanda	1
OM - Oman	1
PT - Portogallo	1
SA - Arabia Saudita	1
SI - Slovenia	1
SN - Senegal	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	1.416

Nome	#
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC)	264
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)]	261
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study	258
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis	191
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis	112
Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)	110
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population	91
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy	74
ECG/echo indexes in the diagnostic approach to amyloid cardiomyopathy: A head-to-head comparison from the AC-TIVE study	69
Totale	1.430

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2024/2025	37	0	0	0	0	0	0	0	0	0	0	8	29
2025/2026	1.090	36	128	128	150	82	70	78	86	130	94	44	64
2026/2027	303	46	51	111	95	0	0	0	0	0	0	0	0
Totale													1.430